Medibact GuidesShop at Medibact

Tesamorelin Dosage: Label Daily Dose, Units and Water

The three Egrifta labels' daily doses of 2, 1.4 and 1.28 mg and their reconstitution volumes, dated, plus the units for 5 mg and 10 mg research vials.

Medibact Guides · Published 2026-09-18

Illustration: A clear glass vial with measured drops of clear liquid and a stirring rod on a white lab bench.
Illustration

Tesamorelin is the exception on this site. Every other compound here either has no label or has a label for a pen, but tesamorelin has three labels for a powder in a vial, each stating a daily dose, a diluent volume and the concentration that results. That makes it the one compound where "how many units" has a label-backed answer, and where the research-vial arithmetic can be laid beside a regulator's own version of the same sum. This page reports the three labels and the trials behind them, dated, and then works the 5 mg and 10 mg vials.

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone with a stabilising modification at its N-terminus, developed by Theratechnologies and sold as Egrifta. Medibact's Tesamorelin guide covers the molecule and its evidence; this page stays with figures. The dosage hub lists every compound's page.

What the sources state

Source Kind Figure Date read
Egrifta SV label, Theratechnologies (revised 2/2024; DailyMed version published 2026-07-31) Approved label 1.4 mg subcutaneously once daily; 2 mg vial + 0.5 mL Sterile Water for Injection = 2 mg per 0.5 mL; 0.35 mL drawn, remainder discarded; 30 vials per box 2026-09-18
Egrifta WR label, Theratechnologies (revised 3/2025; DailyMed version published 2026-08-03) Approved label 1.28 mg subcutaneously once daily; 11.6 mg vial + 1.3 mL Bacteriostatic Water for Injection, USP = 8 mg/mL; 0.16 mL drawn; seven days per vial; four vials per box 2026-09-18
Egrifta, BLA 022505 (Drugs@FDA; approved 2010-11-10; 1 mg vials) Approved product 2 mg once daily from two 1 mg vials, the pivotal-trial regimen 2026-09-18
Falutz et al., NEJM 2007 (PMID 18057338) Trial publication 2 mg subcutaneously once daily for 26 weeks; visceral adipose tissue -15.2% vs +5.0% placebo 2026-09-18
NCT00123253 (412 participants) and NCT00608023 (263 participants, extension) Trial protocol The two phase 3 registrations behind the 2010 approval 2026-09-18
ClinicalTrials.gov search, "tesamorelin" Registry 24 records; daily doses of 1, 1.28, 1.4 and 2 mg; all subcutaneous, all once daily 2026-09-18
Clinic and vendor "protocol" pages Commonly cited 1 to 2 mg once daily; five days on, two off; three-month cycles with rest months 2026-09-18

Three points stand out. The labelled dose has fallen over fifteen years, from 2 mg to 1.4 mg to 1.28 mg, with each new presentation. Every trial and every label is once daily and subcutaneous, without exception. And the cycling patterns on clinic pages appear in none of the eight primary rows.

The label's own arithmetic

Egrifta SV reconstitutes a 2 mg vial in 0.5 mL, so the solution is 4 mg/mL, and the labelled 0.35 mL dose is 1.4 mg; on a U-100 syringe 0.35 mL is 35 units. Egrifta WR states its concentration directly, 8 mg/mL, and its 0.16 mL dose is 1.28 mg, or 16 units. Seven such doses are 1.12 mL, which is why the label describes one vial as a seven-day supply. The original product needed two 1 mg vials for its 2 mg dose. Those are the only unit figures on this page that come from a label rather than from arithmetic.

Units per dose at each research-vial size

Research-market tesamorelin is supplied in 5 mg and 10 mg vials. The table takes each at 1, 2 and 3 mL of water, states the concentration, and converts the four figures in the record, 1 mg (SMART), 1.28 mg (Egrifta WR), 1.4 mg (Egrifta SV) and 2 mg (Egrifta and the pivotal trial), into U-100 syringe units (100 units = 1 mL).

Vial Water added Concentration 1 mg 1.28 mg 1.4 mg 2 mg
5 mg 1 mL 5 mg/mL 20 25.6 28 40
5 mg 2 mL 2.5 mg/mL 40 51.2 56 80
5 mg 3 mL 1.67 mg/mL 60 76.8 84 120 (>1 syringe)
10 mg 1 mL 10 mg/mL 10 12.8 14 20
10 mg 2 mL 5 mg/mL 20 25.6 28 40
10 mg 3 mL 3.33 mg/mL 30 38.4 42 60

The 1.28 mg and 1.4 mg columns produce fractional units at most concentrations, which is a consequence of the labels being written for their own vial sizes rather than for these. A 5 mg vial at 5 mg/mL holds two and a half of the 2 mg amounts, and a 10 mg vial at the same concentration holds five. The tesamorelin calculator works any combination entered. Water volume per vial size, the resulting concentration and the units for the labelled amounts are worked through on the tesamorelin reconstitution page.

What the figures omit

The labels attach a single indication, HIV-associated lipodystrophy in adults, and a set of monitoring and contraindication statements that belong to the finished product. The pivotal trial attaches a 26-week duration and a population defined by HIV and abdominal fat; the academic trials attach their own populations. The clinic pages attach cycles that no label or trial contains. A research vial attaches none of these, and the arithmetic above moves only the milligram figures. One registry record is worth a separate mention: NCT07481734, first posted 2026-03-19, proposes 2 mg daily and carries "Mock Study" in its title; it is reported here as it appears, and it is not evidence of anything.

Sermorelin dosage reports the other growth-hormone-releasing peptide on this site, whose label was withdrawn. The tesamorelin and ipamorelin stack article covers the combination readers most often search alongside it, and the blend calculator works two-vial arithmetic. Storage after mixing is the store's subject: medibact.com's how to store peptides page covers it, and its how to reconstitute peptides page covers the general procedure.

The insulin syringe units how-to explains the U-100 and U-40 scales and how a milligram figure becomes a syringe reading.

What this page does not do

This page reports what three labels, one pivotal trial, the registry and the public web state about tesamorelin dosing, each with its source and date, and converts the sourced figures into syringe units for the two research-vial sizes. It does not recommend an amount, a schedule or a cycle, and it does not extend the labels' indication to any other use. The label figures are reported for the products the labels cover; the tables are arithmetic, not a plan.

Sources and dates

Opened 2026-09-18: the Egrifta SV label on DailyMed (set id 3d783378-b02d-4f19-99dd-0fc91a042224, revised 2/2024) and the Egrifta WR label on DailyMed (set id 839334d3-8c1d-4c26-9036-2ab524a6ea75, revised 3/2025); the Drugs@FDA record for BLA 022505 through the openFDA endpoint; PMID 18057338 (Falutz et al., NEJM 2007); NCT00123253, NCT00608023 and NCT07481734 on ClinicalTrials.gov, and the registry search for tesamorelin (24 records); and a read of clinic and vendor protocol pages for the figures in circulation. Corrections go to the contact page.

Frequently asked questions

What is the tesamorelin dosage on the label?

It depends on the product. Egrifta SV states 1.4 mg once daily, as 0.35 mL of a 2 mg vial reconstituted with 0.5 mL of sterile water. Egrifta WR states 1.28 mg once daily, as 0.16 mL of an 8 mg/mL solution from an 11.6 mg vial reconstituted with 1.3 mL of bacteriostatic water. The original 2010 Egrifta was 2 mg once daily from 1 mg vials. All three were read on DailyMed or Drugs@FDA on 2026-09-18, and all three are for HIV-associated lipodystrophy.

What is the tesamorelin protocol in the trials?

The pivotal trial (Falutz et al., NEJM 2007, PMID 18057338) gave 2 mg subcutaneously once daily for 26 weeks, and the extension (NCT00608023) continued to 52 weeks. Later academic trials used 1 mg (SMART, 20 weeks), 1.4 mg (a fatty-liver study) and 1.28 mg (a 2025 exercise study) once daily. The five-on, two-off cycling on clinic pages appears in no registered trial and no label; it is a clinic convention.

How many units is 2 mg of tesamorelin?

At 5 mg/mL, which a 5 mg vial reaches with 1 mL of water and a 10 mg vial with 2 mL, 2 mg is 0.4 mL, which is 40 units on a U-100 syringe. At 10 mg/mL it is 20 units, at 2.5 mg/mL 80 units, and at 1.67 mg/mL 120 units, more than one syringe. The Egrifta labels never reach 2 mg in one draw from the current products; the 2 mg figure belongs to the 2010 product and the 2007 trial.

How much water goes in a 5 mg tesamorelin vial?

No label covers a 5 mg research vial. The labelled products state their own volumes: 0.5 mL of sterile water into a 2 mg vial (Egrifta SV, giving 2 mg per 0.5 mL) and 1.3 mL of bacteriostatic water into an 11.6 mg vial (Egrifta WR, giving 8 mg/mL). For a 5 mg vial the arithmetic is 1 mL for 5 mg/mL, 2 mL for 2.5 mg/mL and 3 mL for 1.67 mg/mL; the table on this page converts each label figure at every one of them.

Why does Egrifta WR use bacteriostatic water?

Because it is a multi-day vial. The WR label states that one 11.6 mg vial, reconstituted with 1.3 mL of Bacteriostatic Water for Injection, USP, provides seven daily 0.16 mL doses, and a preserved diluent is what allows repeated entry into the same vial. Egrifta SV, a single-day vial, uses Sterile Water for Injection and discards the remainder after the 0.35 mL dose. The storage conditions after mixing are the label's and medibact.com's storage article covers the subject.

Is tesamorelin approved for anything other than HIV lipodystrophy?

No. Each of the three Egrifta labels read on 2026-09-18 carries a single indication: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Academic trials have tested it in fatty liver disease, cognition, ageing and peripheral nerve injury, at 1 to 2 mg daily, but none of those uses appears on a label, and no label covers the 5 mg and 10 mg vials sold for research.